Biogen (NASDAQ:BIIB) Rating Reiterated by Needham & Company LLC
MarketBeatNeedham & Company LLC reaffirmed a “buy” rating and set a $285.00 price target on shares of Biogen in a report on Tuesday.
Needham & Company LLC reaffirmed a “buy” rating and set a $285.00 price target on shares of Biogen in a report on Tuesday.